Johnson & Johnson
NYSE: JNJ
$155.47
-$1.26 (-0.8%)
Closing Price on November 8, 2024
JNJ Articles
The U.S. economy is primarily driven by consumer spending. To put it another way, the country’s economy depends, to a large extent, on the private sector’s ability to identify — and sell —...
Published:
Investors are drawn to dividend stocks for their reliable income and the potential for a robust total return. Total return encompasses interest, capital gains, dividends, and distributions...
Published:
Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations have contributed 68%. Therefore, sustainable dividend income and capital...
Published:
On the cover of the Friday, April 12, 2024 edition of The Wall Street Journal, the headline read: “Cost of Owning a Home Soars”. The article cited one family whose home insurance costs had risen...
Published:
After years of a low-interest rate environment, which has reversed significantly over the last two years, many investors continue to turn to equities for growth potential and solid and dependable...
Published:
In today’s episode of the 24/7 finance series analyst Jeremy Phillips and Austin Smith discuss rebounding inflation, and two stocks for investors to look at today. In inflationary times many...
Published:
Over the last two years, interest rates have jumped from historical lows of literally 0% to the highest level since 2007 at 5.5%. 30 FHA Mortgages have jumped from 2.65% in January of 2021 to the...
Published:
The aging population and increasing life expectancy of Baby Boomers have created a growing demand for investments that provide reliable income and the potential for long-term growth. High-yield...
Published:
Last Updated:
In the high-stakes world of investing, the late great Charlie Munger’s playbook stands out for its focus on fundamental strength and long-term value—principles that have cemented his legacy...
Published:
Here is an assessment of how safe the dividend at AbbVie appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Published:
Here is an assessment of how safe the dividend at Abbott Laboratories appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Published:
Everything is starting to look rosy again. The inflation data for November came in below the estimates, earnings have been reasonably good for the third quarter, and investors just celebrated a...
Published:
The Johnson brothers started Johnson & Johnson in 1886 JHVEPhoto / iStock Editorial via Getty Images The iconic healthcare giant was started by Robert, James, and Edward Johnson in 1886 after...
Published:
With November here, many investors are looking toward Thanksgiving, the holidays, and the end of the year. The stock market went through some of the biggest combined net selling from August to...
Published:
If any investor has stood the test of time, it’s Warren Buffett, and with good reason. For years the “Oracle of Omaha” has had a rock star-like presence in the investing world, and his annual...
Published: